IDH1 and astrocytoma (excluding glioblastoma): For patients with astrocytoma, there were significant survival differences between IDH-mutant and IDH-wildtype tumors (IDH-mutant 1-year OS, 91% [81–100%] vs. IDH-wildtype 1-year OS, 63% [46–85%]; p = 0.049), irrespective of the grade (Figure 8).